Multidisciplinary Therapy in Men with Newly Diagnosed Oligometastatic Prostate Cancer

Area of Science:

• Oncology
• Radiation Oncology
• Urologic Oncology

Background:

• Oligometastatic prostate cancer presents a unique clinical challenge, bridging localized and widely metastatic disease.
• Systemic therapy, primarily androgen deprivation therapy (ADT), is standard but local control of metastases is debated.
• Assessing aggressive local therapy combined with systemic treatment is crucial for optimizing patient outcomes.

Observation:

• This study evaluated 12 patients with oligometastatic prostate cancer receiving ADT followed by local therapy.
• Local therapy included radiation or surgery for the prostate and radiation for all metastatic sites (bone and lymph nodes).
• Follow-up included continued ADT and monitoring of prostate-specific antigen (PSA) and testosterone levels.

Findings:

• The combined approach demonstrated a promising trend for managing oligometastatic prostate cancer.
• Patients who did not progress to castration-resistant prostate cancer (CRPC) showed significant differences in PSA levels before and after local therapies compared to those who did progress.
• One patient achieved undetectable PSA levels post-treatment with recovered testosterone.

Implications:

• Aggressive local therapy alongside ADT represents a potentially effective strategy for select patients with oligometastatic prostate cancer.
• This multimodal approach may improve disease control and delay the onset of castration resistance.
• Further research with larger cohorts is warranted to confirm these findings and refine treatment protocols.